VCYT
Price:
$40.99
Market Cap:
$3.18B
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to hel...[Read more]
Industry
Biotechnology
IPO Date
2013-10-30
Stock Exchange
NASDAQ
Ticker
VCYT
According to Veracyte, Inc.’s latest financial reports and current stock price. The company's current ROE is -0.83%. This represents a change of 206.66% compared to the average of -0.27% of the last 4 quarters.
The mean historical ROE of Veracyte, Inc. over the last ten years is -33.43%. The current -0.83% ROE has changed -97.52% with respect to the historical average. Over the past ten years (40 quarters), VCYT's ROE was at its highest in in the September 2024 quarter at 1.29%. The ROE was at its lowest in in the June 2016 quarter at -33.31%.
Average
-33.43%
Median
-18.67%
Minimum
-83.29%
Maximum
-3.40%
Discovering the peaks and valleys of Veracyte, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 109.57%
Maximum Annual ROE = -3.40%
Minimum Annual Increase = -76.13%
Minimum Annual ROE = -83.29%
Year | ROE | Change |
---|---|---|
2023 | -7.13% | 109.57% |
2022 | -3.40% | -50.66% |
2021 | -6.89% | -19.02% |
2020 | -8.51% | 23.64% |
2019 | -6.88% | -76.13% |
2018 | -28.84% | -65.38% |
2017 | -83.29% | 58.24% |
2016 | -52.63% | -19.97% |
2015 | -65.76% | -7.37% |
2014 | -70.99% | 56.65% |
The current ROE of Veracyte, Inc. (VCYT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-5.81%
5-year avg
-6.56%
10-year avg
-33.43%
Veracyte, Inc.’s ROE is greater than Crinetics Pharmaceuticals, Inc. (-36.12%), greater than Viridian Therapeutics, Inc. (-45.47%), less than Cytokinetics, Incorporated (335.19%), greater than Structure Therapeutics Inc. (-16.40%), greater than Icosavax, Inc. (-20.22%), greater than Kura Oncology, Inc. (-44.09%), less than Protagonist Therapeutics, Inc. (34.68%), greater than Merus N.V. (-45.38%), greater than Replimune Group, Inc. (-53.12%), greater than Cerevel Therapeutics Holdings, Inc. (-98.94%), greater than Enanta Pharmaceuticals, Inc. (-73.02%), greater than Syndax Pharmaceuticals, Inc. (-64.34%), greater than Ventyx Biosciences, Inc. (-54.94%), greater than uniQure N.V. (-188.82%), greater than Rocket Pharmaceuticals, Inc. (-62.62%), greater than Rhythm Pharmaceuticals, Inc. (-369.26%), greater than Solid Biosciences Inc. (-58.75%), greater than MeiraGTx Holdings plc (-80.95%), greater than IDEAYA Biosciences, Inc. (-19.42%), greater than AnaptysBio, Inc. (-287.94%), greater than Keros Therapeutics, Inc. (-41.74%), greater than Homology Medicines, Inc. (-100.91%),
Company | ROE | Market cap |
---|---|---|
-36.12% | $5.00B | |
-45.47% | $1.56B | |
335.19% | $5.78B | |
-16.40% | $1.64B | |
-20.22% | $769.04M | |
-44.09% | $695.21M | |
34.68% | $2.42B | |
-45.38% | $2.91B | |
-53.12% | $929.70M | |
-98.94% | $8.19B | |
-73.02% | $135.01M | |
-64.34% | $1.14B | |
-54.94% | $166.17M | |
-188.82% | $849.59M | |
-62.62% | $1.22B | |
-369.26% | $3.44B | |
-58.75% | $163.81M | |
-80.95% | $475.95M | |
-19.42% | $2.19B | |
-287.94% | $425.09M | |
-41.74% | $693.49M | |
-100.91% | $3.02M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Veracyte, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Veracyte, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Veracyte, Inc.'s ROE?
How is the ROE calculated for Veracyte, Inc. (VCYT)?
What is the highest ROE for Veracyte, Inc. (VCYT)?
What is the 3-year average ROE for Veracyte, Inc. (VCYT)?
What is the 5-year average ROE for Veracyte, Inc. (VCYT)?
How does the current ROE for Veracyte, Inc. (VCYT) compare to its historical average?